Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETHIC: Early thromboprophylaxis in community-based COVID-19
2020-003125-39Phase 3Completed
- Sponsor
- Thrombosis Research Institute
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Prophylactic enoxaparin with Standard of care (no enoxaparin) (2 arms). Primary endpoint: Primary composite endpoint. Started Sep 2020; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003125-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003125-39.